Pharmacokinetic and bioequivalence of two formulations of Valsartan/Amlodipine Tablet(I) in healthy Chinese volunteers: A randomized, three-period, partially replicated crossover study
Yingying Mei, Xu Zuo, Tiandong Zhang, Ziyun Bu, Zhendan Xu · 2025
Read Pharmacokinetic and bioequivalence of two formulations of Valsartan/Amlodipine Tablet(I) in healthy Chinese volunteers: A randomized, three-period, partially replicated crossover study by Yingying Mei, Xu Zuo, Tiandong Zhang, Ziyun Bu, Zhendan Xu (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12824408.txt.
Description
Yingying Mei and co-authors report a drug trial run in China and published in 2025. The team tested a new generic tablet that joins two blood pressure drugs, valsartan and amlodipine, in one pill. They set out to learn whether the new tablet acts in the body the same way as the tablet already on the market.
The trial used a crossover design, so each of the 72 healthy volunteers took both forms of the drug in turn, under fasting and fed conditions. Blood tests tracked how much of each drug reached the blood over time. The new tablet matched the older one closely, and no serious side effects appeared. The results support selling the generic tablet in China.
Catalog record
| CREATOR | Yingying Mei, Xu Zuo, Tiandong Zhang, Ziyun Bu, Zhendan Xu |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |